Latest news

• Rare disease therapies head the ‘class of 2015’

  EU. cariprazine. Vraylar. schizophrenia / bipolar disorder. dopamine D3/D2 receptor partial agonist.

• Allergan and Gedeon finally get antipsychotic green light

  Vraylar (cariprazine) is a dopamine D2, D3 receptor partial agonist and was turned down by the FDA in 2013, with the agency requesting more data including another clinical trial despite acknowledging ... Analysts at Canaccord Genuity have indicated they

• More waiting for Allergan and Gedeon Richter's antipsychotic

  end of 2013, despite concluding that cariprazine showed efficacy in the two indications. ... Analysts at Canaccord Genuity said last month that they expect cariprazine to have $500m annual peak sales potential.

• J&J gets quicker review for schizophrenia depot in US

  in the summer, as well as two novel antipsychotics - Otsuka/Lundbeck's brexpiprazole and cariprazine from Actavis and Gedeon Richter. ... Cariprazine was turned down by the FDA towards the end of 2013 but has just shown activity in a new phase III trial,

• Forest said to be interested in $3bn Aptalis acquisition

  decision to delay approval of its schizophrenia candidate cariprazine last November.